TY - JOUR AU - Sahni, S. AU - Valecha, G. AU - Sahni, A. PY - 2018 DA - 2018// TI - Role of anti-PD-1 antibodies in advanced melanoma: the era of immunotherapy JO - Cureus. VL - 10 ID - Sahni2018 ER - TY - JOUR AU - Ribas, I. AU - Puzanov, R. D. PY - 2015 DA - 2015// TI - Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00083-2 DO - 10.1016/S1470-2045(15)00083-2 ID - Ribas2015 ER - TY - JOUR AU - Morales-Barera, R. AU - Rodriguez, C. S. AU - Gonzalez, M. AU - Ros, J. AU - Semidey, M. E. AU - Hernandez, E. S. PY - 2019 DA - 2019// TI - Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors JO - J Clin Oncol. VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.4531 DO - 10.1200/JCO.2019.37.15_suppl.4531 ID - Morales-Barera2019 ER - TY - JOUR AU - Braaten, T. J. AU - Brahmer, J. R. AU - Forde, P. M. PY - 2020 DA - 2020// TI - Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation JO - Ann Rheum Dis VL - 79 UR - https://doi.org/10.1136/annrheumdis-2019-216109 DO - 10.1136/annrheumdis-2019-216109 ID - Braaten2020 ER - TY - JOUR AU - Asher, N. AU - Marom, E. M. AU - Ben-Betzalel, G. AU - Baruch, E. N. AU - Steinberg-Silman, Y. AU - Schachter, J. AU - Shapira-Frommer, R. AU - Markel, G. PY - 2019 DA - 2019// TI - Recurrent pneumonitis in patients with melanoma treated with immune checkpoint inhibitors JO - Oncologist VL - 24 UR - https://doi.org/10.1634/theoncologist.2018-0352 DO - 10.1634/theoncologist.2018-0352 ID - Asher2019 ER - TY - JOUR AU - Jong, C. AU - Peters, B. AU - Schramel, F. PY - 2018 DA - 2018// TI - Recurrent episodes of nivolumab induced pneumonitis after nivolumab discontinuation and the time course of carcinoembryonic antigen levels: a case of a 58-year-old woman with non-small cell lung cancer JO - Chemotherapy. VL - 63 UR - https://doi.org/10.1159/000494841 DO - 10.1159/000494841 ID - Jong2018 ER - TY - JOUR AU - Marthey, L. AU - Mateus, C. AU - Mussini, C. PY - 2016 DA - 2016// TI - Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease JO - J Crohns Colitis. VL - 10 UR - https://doi.org/10.1093/ecco-jcc/jjv227 DO - 10.1093/ecco-jcc/jjv227 ID - Marthey2016 ER - TY - JOUR AU - Kikuchi, H. AU - Sakuraba, H. AU - Akemoto, Y. AU - Murai, Y. AU - Fukutoku, Y. AU - Asari, T. AU - Tatsuta, T. AU - Hasui, K. AU - Hiraga, H. AU - Sawaya, M. AU - Chinda, D. AU - Mikami, T. AU - Tanaka, M. AU - Fukuda, S. PY - 2019 DA - 2019// TI - A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine JO - Immunol Med VL - 42 UR - https://doi.org/10.1080/25785826.2019.1580477 DO - 10.1080/25785826.2019.1580477 ID - Kikuchi2019 ER - TY - JOUR AU - Chen, J. H. AU - Pezhouh, M. K. AU - Lauwers, G. Y. AU - Masia, R. PY - 2017 DA - 2017// TI - Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies JO - Am J Surg Pathol. VL - 41 UR - https://doi.org/10.1097/PAS.0000000000000829 DO - 10.1097/PAS.0000000000000829 ID - Chen2017 ER - TY - JOUR AU - Johnson, D. H. AU - Zobniw, C. M. AU - Trinh, V. A. PY - 2018 DA - 2018// TI - Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis JO - J Immuno Therapy Cancer. VL - 6 UR - https://doi.org/10.1186/s40425-018-0412-0 DO - 10.1186/s40425-018-0412-0 ID - Johnson2018 ER - TY - JOUR AU - Touat, M. AU - Maisonobe, T. AU - Knauss, S. PY - 2019 DA - 2019// TI - Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer JO - Neurology. VL - 93 UR - https://doi.org/10.1212/WNL.0000000000007380 DO - 10.1212/WNL.0000000000007380 ID - Touat2019 ER - TY - JOUR AU - Beardslee, T. AU - Draper, A. AU - Kudchadkar, R. PY - 2019 DA - 2019// TI - Tacrolimus for the treatment of immune related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy JO - J Oncol Pharm Pract VL - 25 UR - https://doi.org/10.1177/1078155218793709 DO - 10.1177/1078155218793709 ID - Beardslee2019 ER - TY - JOUR AU - Ribas, A. AU - Puzanov, I. AU - Dummer, R. PY - 2015 DA - 2015// TI - Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00083-2 DO - 10.1016/S1470-2045(15)00083-2 ID - Ribas2015 ER - TY - JOUR AU - Kuint, R. AU - Lotem, M. AU - Neuman, T. AU - Bekker-Milovanov, E. AU - Abutbul, A. AU - Laxer, U. AU - Berkman, N. AU - Fridlender, Z. G. PY - 2017 DA - 2017// TI - Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma—a case report JO - Respir Med Case Rep VL - 20 ID - Kuint2017 ER - TY - JOUR AU - Jour, G. AU - Glitza, I. C. AU - Ellis, R. M. PY - 2016 DA - 2016// TI - Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions JO - J Cutan Pathol VL - 43 UR - https://doi.org/10.1111/cup.12717 DO - 10.1111/cup.12717 ID - Jour2016 ER - TY - JOUR AU - Wang, L. AU - Patel, G. AU - Chiesa-Fuxench, Z. PY - 2018 DA - 2018// TI - Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy JO - JAMA Dermatol VL - 154 UR - https://doi.org/10.1001/jamadermatol.2018.1912 DO - 10.1001/jamadermatol.2018.1912 ID - Wang2018 ER - TY - JOUR AU - Jour, G. PY - 2016 DA - 2016// TI - Autoimmune dermatologic toxicities from autoimmune checkpoint inhibitor blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions JO - J Cutan Pathol. VL - 43 UR - https://doi.org/10.1111/cup.12717 DO - 10.1111/cup.12717 ID - Jour2016 ER - TY - JOUR AU - Yoest, J. M. PY - 2017 DA - 2017// TI - Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review JO - Immunotargets Ther. VL - 6 UR - https://doi.org/10.2147/ITT.S126227 DO - 10.2147/ITT.S126227 ID - Yoest2017 ER - TY - JOUR AU - Brahmer, J. R. AU - Lacchetti, C. AU - Schneider, B. J. PY - 2018 DA - 2018// TI - Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline JO - J Clin Oncol. VL - 36 UR - https://doi.org/10.1200/JCO.2017.77.6385 DO - 10.1200/JCO.2017.77.6385 ID - Brahmer2018 ER - TY - JOUR AU - Puzanov, I. AU - Diab, A. AU - Abdallah, K. PY - 2017 DA - 2017// TI - Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group JO - J Immunother Cancer. VL - 5 UR - https://doi.org/10.1186/s40425-017-0300-z DO - 10.1186/s40425-017-0300-z ID - Puzanov2017 ER -